Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : A Biotech Bonanza! -- Ignore unavailable to you. Want to Upgrade?

To: Alys Hall who wrote (17)	10/22/1997 7:10:00 AM
From: F. Jay Abella, III	Read Replies (3) \| Respond to of 64

Hey GS and AH: Great idea to start this thread. I don't know if it will make my job easier or harder :). You have picked the best company to start your discussion. Any others that you ever discuss, to me, should be compared either overtly or in the back of your mind to SUPG. Insodoing, ask yourselves the following when assessing the downside risks for investing in biotech companies (in no particular order). 1) Do its products serve large markets? 2) Does it have an management team with experience in COMMERCIALIZING PRODUCTS (and not just raising money)? 3) Can it collaborate appropriately? 4) How well has it used its cash? 5) Is the company in a position to actually sell products within the next year (the "sales first" approach)? 5a) If so, will it be profitable without having to incur additional dilution? (Note - affirmative response to this question may make its share price less volatile in a changing interest rate environment). 6) Are its technologies patent protected? 7) Can it sustain interest for its stock over time? To me, SUPG has all of these characteristics. In fact, as I have told numerous reporters and publications, that there is not a better example of a biotech company whose organization is designed to fit the realities of the drug approval and FDA regulatory process. This alignment of incentives is a direct result of a management who KNOWS THE DRUG BUSINESS. A dying breed in biotech indeed. I will mention this thread at my homepage this week. FJA